TAM receptors Tyro3 and Mer as novel targets in colorectal cancer
CRC remains the third most common cancer worldwide with a high 5-year mortality rate in advanced cases. Combined with chemotherapy, targeted therapy is an additional treatment option. However as CRC still escapes targeted therapy the vigorous search for new targets is warranted to increase patients´...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
July 28, 2016
|
| In: |
OncoTarget
Year: 2016, Jahrgang: 7, Heft: 35, Pages: 56355-56370 |
| ISSN: | 1949-2553 |
| DOI: | 10.18632/oncotarget.10889 |
| Online-Zugang: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.18632/oncotarget.10889 Verlag, lizenzpflichtig, Volltext: https://www.oncotarget.com/article/10889/text/ |
| Verfasserangaben: | Robin Schmitz, Aida Freire Valls, Rosario Yerbes, Sophie von Richter, Christoph Kahlert, Sonja Loges, Jürgen Weitz, Martin Schneider, Carmen Ruiz de Almodovar, Alexis Ulrich, Thomas Schmidt |
| Zusammenfassung: | CRC remains the third most common cancer worldwide with a high 5-year mortality rate in advanced cases. Combined with chemotherapy, targeted therapy is an additional treatment option. However as CRC still escapes targeted therapy the vigorous search for new targets is warranted to increase patients´ overall survival. |
|---|---|
| Beschreibung: | Gesehen am 19.05.2020 |
| Beschreibung: | Online Resource |
| ISSN: | 1949-2553 |
| DOI: | 10.18632/oncotarget.10889 |